How much funding does NIH SBIR provide?

Award size and terms depend on the active solicitation. Key figures to verify: Typical award range: Per NIH SBIR/STTR Omnibus or FOA caps Institute FOAs may differ from Omnibus budget caps. Award duration: Phase I/II standard NIH periods Cost share: Usually none Confirm ceilings, option years, and match requirements on the active notice before budgeting a proposal.

Is NIH SBIR currently open / accepting applications?

Open status changes with new notices, amendments, and appropriations. Check the following before you commit proposal resources: Active — Omnibus and institute FOAs Opportunities are generally open—confirm the active solicitation and deadline on the official agency page. Check NIH SEED and Grants.gov for live FOAs. Release cadence: Standard NIH receipt dates + special FOAs Status last verified 2026-07-12

How do you apply for NIH SBIR?

Follow the published process for the active solicitation. In most cases, the sequence looks like this: Institute and FOA selection Specific aims and research strategy drafting ASSIST package and submission Peer review and summary statement response planning

What are NIH SBIR proposal requirements?

Reviewers expect a complete package that addresses the notice instructions. Core requirements usually include: Specific aims clarity Significance, innovation, approach Commercialization / product path Team and environment

What do NIH SBIR reviewers look for?

Evaluation criteria vary by solicitation, but reviewers consistently score proposals on: Significance Investigators Innovation Approach Environment

What are common NIH SBIR application mistakes?

Weak submissions often fail for predictable reasons: Aims that are too broad for Phase I Ignoring institute priorities Commercialization as an afterthought

How long does a NIH SBIR pursuit typically take?

Timeline depends on solicitation complexity and internal readiness. A typical Velawolf-supported pursuit follows these phases: Weeks 1–2: Institute fit and aims workshop Weeks 3–8: Research strategy and commercialization drafting Weeks 8–10: ASSIST compliance and submit Post-review: Summary statement strategy

When should you not apply for NIH SBIR?

Skip or pause a NIH SBIR pursuit when fit is weak. Common stop conditions include: Your project is academic-owned with no small-business PI eligibility. You need countermeasure stockpile logic—consider BARDA instead. Your ask is transformative health moonshot work better framed for ARPA-H than NIH SBIR. You cannot meet NIH registration, Human Subjects, or Vertebrate Animals requirements the NOFO imposes.

How does NIH SBIR compare to related federal pathways?

Choose NIH SBIR only when it is the best mechanism fit. Useful comparisons: Choose Omnibus vs an institute FOA deliberately—institute FOAs when special priorities or budget caps fit; Omnibus for broader parent announcements. Choose BARDA instead when you need medical countermeasure contracting rather than NIH small-business R&D phases. Choose ARPA-H instead when the concept is a high-risk health moonshot outside NIH SBIR peer-review norms. Choose NIAID or another institute grant path instead when you need R01-style science rather than SBIR commercialization phases.

What registrations and readiness items are needed for NIH SBIR?

Confirm administrative readiness before proposal spend: eRA Commons accounts for PI and small-business official SAM.gov / UEI and Grants.gov readiness Omnibus vs institute FOA decision documented SBA Company Registry current Commercialization plan outline and customer discovery notes Human subjects / clinical trial documentation if applicable

Fit checklist 1: Is my program ready for NIH SBIR / STTR?

Correct institute and FOA selected

Fit checklist 3: Is my program ready for NIH SBIR / STTR?

Regulatory path sketched if device/drug/diagnostic

Fit checklist 4: Is my program ready for NIH SBIR / STTR?

Company PI / eligibility confirmed

NIH SBIR / STTR: Eligibility, Institutes, and How to Apply

Eligibility, typical funding (Per NIH SBIR/STTR Omnibus or FOA caps), how to apply, review criteria, open status, fit checklist, pursuit examples, and official sources for NIH SBIR. Last reviewed 2026-07-12.

Agency: U.S. National Institutes of Health — institute and center SBIR/STTR programs. Mechanism: Phased SBIR/STTR Omnibus and institute-specific FOAs via Grants.gov / ASSIST.

Status: Active — Omnibus and institute FOAs

Typical funding: Per NIH SBIR/STTR Omnibus or FOA caps

What is NIH SBIR?

NIH SBIR/STTR funds small businesses developing biomedical and health technologies. Institute fit (NCI, NHLBI, NIAID, and others), clinical path realism, and regulatory awareness matter as much as scientific novelty.

NIH SBIR/STTR spans Omnibus solicitations and institute-specific FOAs, each with different budget caps, receipt dates, and review expectations. Commercialization plans and human-subjects rigor matter more than on many DoD topics. BARDA and ARPA-H sit nearby for countermeasure contracting and moonshot health R&D outside classic SBIR phases.

NIH SBIR / STTR is administered by U.S. National Institutes of Health — institute and center SBIR/STTR programs. The funding mechanism is Phased SBIR/STTR Omnibus and institute-specific FOAs via Grants.gov / ASSIST. This guide covers eligibility, funding size, how to apply, reviewer expectations, open status, and fit—so you can decide whether to pursue before writing.

Program goals

Advance health technologies toward clinical or commercial use
Support small-business biomedical innovation
Bridge academic discovery into company-led development

Recent program activity

Check NIH SEED and Grants.gov for live FOAs.

Who NIH SBIR funding is for

U.S. small businesses meeting SBA rules; STTR requires a research-institution partner. Specific FOAs may add clinical or disease-area constraints.

Biotech, MedTech, diagnostics, and digital health small businesses.

If your technology does not map to NIH SBIR mission priorities, stop here and compare related pathways before drafting.

Strong-fit applicant profiles

Biotech, MedTech, diagnostics, and digital health small businesses
University spinouts with defined company ownership of the project
STTR teams with academic collaborators

Usually not a fit

Pure basic science better suited to R01 without company ownership Teams without a credible regulatory or clinical path when required Non-small-business applicants

NIH SBIR eligibility requirements

Confirm SBA small-business eligibility, PI employment rules, and whether Omnibus versus an institute FOA better matches your indication and budget needs. Clinical or regulated product paths must respect NIH human-subjects and commercialization guidance.

Eligibility is notice-specific. Treat the checklist below as the baseline, then verify against the live FOA, BAA, or NOFO.

Key eligibility requirements

Institute / FOA alignment
Human subjects / vertebrate animals compliance when applicable
Commercialization plan appropriate to health products
ASSIST / Grants.gov readiness

NIH SBIR funding amounts and award terms

Institute FOAs may differ from Omnibus budget caps.

Typical award range for NIH SBIR: Per NIH SBIR/STTR Omnibus or FOA caps.

Award duration: Phase I/II standard NIH periods.

Cost share: Usually none.

Ranges change by solicitation. Always confirm ceilings, option years, and cost-share on the active notice.

Is NIH SBIR open right now?

Active — Omnibus and institute FOAs

Check NIH SEED and Grants.gov for live FOAs.

Sunset / authorization note: FOA-specific.

How often opportunities open: Standard NIH receipt dates + special FOAs.

Status changes with appropriations, FOA amendments, and BAA closings. Use the official links in this guide before committing proposal spend.

Status last verified by Velawolf

2026-07-12

NIH SBIR registration and readiness checklist

Administrative readiness decides whether a NIH SBIR package can be submitted on time. Complete these items before funding a full write.

Pre-submission readiness

eRA Commons accounts for PI and small-business official
SAM.gov / UEI and Grants.gov readiness
Omnibus vs institute FOA decision documented
SBA Company Registry current
Commercialization plan outline and customer discovery notes
Human subjects / clinical trial documentation if applicable

How to apply for NIH SBIR

Strong NIH SBIR packages choose Omnibus vs institute FOA deliberately, write aims for NIH peer review, and treat commercialization as substantive—not boilerplate. Copying a DoD transition narrative wholesale usually fails.

Application process steps

Institute and FOA selection
Specific aims and research strategy drafting
ASSIST package and submission
Peer review and summary statement response planning

NIH SBIR proposal / package requirements

Specific aims clarity Significance, innovation, approach Commercialization / product path Team and environment

What NIH SBIR reviewers evaluate

NIH peer review weights significance, innovation, approach, investigators, and environment, plus commercialization credibility for SBIR/STTR.

Review criteria

Significance
Investigators
Innovation
Approach
Environment

Common NIH SBIR application mistakes

Most weak NIH SBIR submissions share the same failure modes: wrong mechanism fit, thin evidence, and late compliance work.

Pitfalls to avoid

Aims that are too broad for Phase I
Ignoring institute priorities
Commercialization as an afterthought

When not to apply for NIH SBIR

Before you fund a NIH SBIR proposal effort, confirm you are not in one of these common mis-fit scenarios:

Stop or switch pathways if…

Your project is academic-owned with no small-business PI eligibility.
You need countermeasure stockpile logic—consider BARDA instead.
Your ask is transformative health moonshot work better framed for ARPA-H than NIH SBIR.
You cannot meet NIH registration, Human Subjects, or Vertebrate Animals requirements the NOFO imposes.

NIH SBIR vs related pathways

Mechanism choice matters more than writing quality. Use these comparisons to confirm NIH SBIR is the right first move—or to switch before drafting.

Pathway comparisons

Choose Omnibus vs an institute FOA deliberately—institute FOAs when special priorities or budget caps fit; Omnibus for broader parent announcements.
Choose BARDA instead when you need medical countermeasure contracting rather than NIH small-business R&D phases.
Choose ARPA-H instead when the concept is a high-risk health moonshot outside NIH SBIR peer-review norms.
Choose NIAID or another institute grant path instead when you need R01-style science rather than SBIR commercialization phases.

NIH SBIR pursuit examples

Illustrative engagement patterns—not award guarantees. Use these to calibrate readiness and pathway fit.

Omnibus vs institute FOA

A diagnostics team defaulted to Omnibus without checking NCI FOAs.

Institute FOA alignment improved reviewer relevance and avoided a generic Omnibus story.

NIH SBIR fit checklist (before you spend)

Use this checklist before funding a full NIH SBIR proposal effort. If several items are missing, fix readiness—or switch pathways—first.

Readiness signals

Correct institute and FOA selected
Phase-appropriate aims scoped
Regulatory path sketched if device/drug/diagnostic
Company PI / eligibility confirmed

Typical NIH SBIR pursuit timeline

Velawolf sequences pursuits around decision gates so teams do not burn calendar on the wrong pathway.

Engagement timeline

Weeks 1–2: Institute fit and aims workshop
Weeks 3–8: Research strategy and commercialization drafting
Weeks 8–10: ASSIST compliance and submit
Post-review: Summary statement strategy

NIH SBIR proposal support: how Velawolf helps

Velawolf supports biotech and MedTech teams on NIH SBIR/STTR Omnibus and institute FOAs.

Work covers institute selection, specific aims, research strategy, and commercialization appropriate to regulated products.

If you need hands-on NIH SBIR proposal support—not just this guide—start with a fit call before proposal spend.

What we deliver

Institute / FOA fit
Specific aims workshop
Research strategy support
ASSIST compliance QA

Official sources

NIH SEED: https://seed.nih.gov/ (NIH SBIR/STTR home)
NIH SEED: https://seed.nih.gov/
NIH SEED: https://seed.nih.gov/

NIH SBIR / STTR FAQ

What is NIH SBIR / STTR? NIH SBIR/STTR funds small businesses developing biomedical and health technologies. Institute fit (NCI, NHLBI, NIAID, and others), clinical path realism, and regulatory awareness matter as much as scientific novelty.
Who is eligible for NIH SBIR? U.S. small businesses meeting SBA rules; STTR requires a research-institution partner. Specific FOAs may add clinical or disease-area constraints. Biotech, MedTech, diagnostics, and digital health small businesses University spinouts with defined company ownership of the project STTR teams with academic collaborators
How much funding does NIH SBIR provide? Award size and terms depend on the active solicitation. Key figures to verify: Typical award range: Per NIH SBIR/STTR Omnibus or FOA caps Institute FOAs may differ from Omnibus budget caps. Award duration: Phase I/II standard NIH periods Cost share: Usually none Confirm ceilings, option years, and match requirements on the active notice before budgeting a proposal.
Is NIH SBIR currently open / accepting applications? Open status changes with new notices, amendments, and appropriations. Check the following before you commit proposal resources: Active — Omnibus and institute FOAs Opportunities are generally open—confirm the active solicitation and deadline on the official agency page. Check NIH SEED and Grants.gov for live FOAs. Release cadence: Standard NIH receipt dates + special FOAs Status last verified 2026-07-12
How do you apply for NIH SBIR? Follow the published process for the active solicitation. In most cases, the sequence looks like this: Institute and FOA selection Specific aims and research strategy drafting ASSIST package and submission Peer review and summary statement response planning
What are NIH SBIR proposal requirements? Reviewers expect a complete package that addresses the notice instructions. Core requirements usually include: Specific aims clarity Significance, innovation, approach Commercialization / product path Team and environment
What do NIH SBIR reviewers look for? Evaluation criteria vary by solicitation, but reviewers consistently score proposals on: Significance Investigators Innovation Approach Environment
What are common NIH SBIR application mistakes? Weak submissions often fail for predictable reasons: Aims that are too broad for Phase I Ignoring institute priorities Commercialization as an afterthought
How long does a NIH SBIR pursuit typically take? Timeline depends on solicitation complexity and internal readiness. A typical Velawolf-supported pursuit follows these phases: Weeks 1–2: Institute fit and aims workshop Weeks 3–8: Research strategy and commercialization drafting Weeks 8–10: ASSIST compliance and submit Post-review: Summary statement strategy
When should you not apply for NIH SBIR? Skip or pause a NIH SBIR pursuit when fit is weak. Common stop conditions include: Your project is academic-owned with no small-business PI eligibility. You need countermeasure stockpile logic—consider BARDA instead. Your ask is transformative health moonshot work better framed for ARPA-H than NIH SBIR. You cannot meet NIH registration, Human Subjects, or Vertebrate Animals requirements the NOFO imposes.
How does NIH SBIR compare to related federal pathways? Choose NIH SBIR only when it is the best mechanism fit. Useful comparisons: Choose Omnibus vs an institute FOA deliberately—institute FOAs when special priorities or budget caps fit; Omnibus for broader parent announcements. Choose BARDA instead when you need medical countermeasure contracting rather than NIH small-business R&D phases. Choose ARPA-H instead when the concept is a high-risk health moonshot outside NIH SBIR peer-review norms. Choose NIAID or another institute grant path instead when you need R01-style science rather than SBIR commercialization phases.
What registrations and readiness items are needed for NIH SBIR? Confirm administrative readiness before proposal spend: eRA Commons accounts for PI and small-business official SAM.gov / UEI and Grants.gov readiness Omnibus vs institute FOA decision documented SBA Company Registry current Commercialization plan outline and customer discovery notes Human subjects / clinical trial documentation if applicable

Velawolf support

Velawolf supports biotech and MedTech teams on NIH SBIR/STTR Omnibus and institute FOAs.

Institute / FOA fit
Specific aims workshop
Research strategy support
ASSIST compliance QA